Re: Persistent COVID-19 in immunocompromised patients-Israeli Society of Infectious Diseases consensus statement on diagnosis and management by Meijer et al

Clin Microbiol Infect. 2024 Sep;30(9):1209-1210. doi: 10.1016/j.cmi.2024.05.011. Epub 2024 May 21.

Authors

Alberto Enrico Maraolo¹, Nicola Schiano Moriello², Ivan Gentile²

Affiliations

¹ Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy. Electronic address: [email protected].
² Section of Infectious Diseases, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

PMID: 38782259
DOI: 10.1016/j.cmi.2024.05.011

No abstract available

Keywords: COVID-19; Duration; Early treatment; Immunocompromised; Persistent infection; Viral shedding.

Publication types

Letter

MeSH terms

COVID-19* / diagnosis
COVID-19* / immunology
Consensus*
Humans
Immunocompromised Host*
SARS-CoV-2* / immunology